
|Articles|January 1, 2004
FDA approves first accommodative IOL
Cataract surgeons who participated in the premarketing clinical trials for the model AT-45 accommodative IOL (Crystalens, eyeonics inc. [formerly C&C Vision]) are heralding that technology as an important advance. The lens affords patients clear uncorrected vision at near, intermediate, and distance. FDA approval for marketing of the lens was granted in November.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
PRIMA retinal implant restores vision in patients with advanced GA
2
Ophthalmology pipeline watch: Key trial results and PDUFA dates for Q1 2026
3
STAAR, Broadwood reach cooperation agreement, restructure board after terminated Alcon deal
4
Ocugen releases positive preliminary 12-month data from phase 2 ArMaDa trial
5














































